For a patient handed a 30-day opioid script after surgery, the road to dependence often begins not in a back alley but in a clinic, on a Tuesday morning, with a prescription that was never tapered down. That handoff, between the prescriber and the patient who keeps refilling, is what Reykjavik-based Prescriby is trying to redesign.
Founded in 2019 by Kjartan Thorsson, Prescriby sells a digital treatment management platform aimed at clinicians who prescribe addictive medications, with a particular focus on opioids [Crunchbase]. The product pairs a treatment generator, which helps a clinician structure a tapering plan at the moment of prescribing, with a dashboard that monitors the patient's progress against that plan over time [Crunchbase]. The patient population is broad and uncomfortably familiar: post-surgical patients, chronic pain patients, and anyone whose first encounter with an opioid is meant to be temporary but quietly is not.
The standard of care today, in most of North America and Europe, leans heavily on the back end of the addiction pipeline. Once a patient is dependent, clinicians reach for medication-assisted treatment such as buprenorphine or methadone, behavioral therapy, and referrals to specialty addiction services. Prescription drug monitoring programs (PDMPs) exist in every U.S. state and in a growing number of European systems, but they function largely as databases that flag risky prescribing patterns after the fact rather than as decision tools at the moment a script is written. Tapering protocols vary widely between clinicians, and structured follow-up after an acute opioid course is not universal. Prescriby's bet is that the highest-use intervention is upstream, at the prescription itself, before a patient ever meets the criteria for opioid use disorder.
In April 2024, the company raised €2 million (roughly $2.1 million) in a seed round led by Reykjavik-based Crowberry Capital [EU-Startups, April 2024]. The round is small by U.S. digital health standards, but Crowberry has been one of the more active early-stage Nordic investors, and the firm's lead position signals conviction in the founding thesis. Prescriby has also begun operating outside Iceland: the company set up what has been described as a tapering clinic in Maine, an early U.S. foothold in a state that has been among the harder-hit by the opioid epidemic [Mainebiz].
Seed round (Apr 2024) | 2.1 | $M
Why this could matter beyond a single Nordic seed round comes down to where regulators and payers are pushing. The CDC's 2022 update to its opioid prescribing guideline reinforced individualized tapering and structured follow-up rather than abrupt discontinuation, and U.S. state attorneys general have continued to pressure health systems on prescribing discipline in the wake of opioid settlements. In Europe, the EMA and national regulators have grown more cautious about long-term opioid use for chronic non-cancer pain. Software that sits inside the prescribing workflow, generates a defensible taper, and produces an audit trail of monitoring is the kind of tool that aligns with where guidelines and liability are both heading. If Prescriby can show that clinics using its platform reduce the share of acute opioid patients who progress to long-term use, the buyers (health systems, insurers, and in some markets national health services) have a clear reason to pay.
Thorsson, the founder, has built the company across an Icelandic and Canadian footprint, and the Maine clinic represents the first operational U.S. presence reported in the press [Mainebiz] [ArcticStartup]. The team is small and the company is at seed stage; public traction figures, peer-reviewed outcomes data, and named health-system customers have not been disclosed in the captured sources. What has been disclosed is a coherent product wedge (the treatment generator plus monitoring dashboard), a lead investor with regional credibility, and a live U.S. deployment in a state where the problem the software addresses is acute.
What bears will say is straightforward. Clinical software that tries to change prescriber behavior is historically slow to sell, hard to integrate with electronic health records, and difficult to prove out without controlled studies. Prescription drug monitoring programs already exist, and a clinician asked to adopt yet another screen during a seven-minute appointment will need a clear reason. The company has not, in the public record, pointed to peer-reviewed evidence that its specific intervention reduces transition to opioid use disorder, and without that evidence the procurement conversation with a large U.S. health system is harder. What bulls answer is that the regulatory and liability environment is doing some of the selling for them: post-settlement, U.S. health systems have a documented interest in being able to demonstrate disciplined opioid stewardship, and a tool that produces a structured taper and a monitoring record is useful even before randomized outcomes data exists. The Maine clinic, if it generates real-world data on tapering completion and refill patterns, could be the wedge that converts the regulatory tailwind into clinical evidence [Mainebiz].
The next twelve months should clarify a few things. Watch for a published outcomes study or a named health-system pilot in the U.S. or Nordics, either of which would move the company from interesting thesis to evidence-backed vendor. Watch the Maine clinic for any disclosed data on patient volumes and tapering outcomes. And watch for a Series A, which on the current $2.1 million seed would likely arrive in 2025 or 2026 if the company hits clinical and commercial milestones. The opioid crisis has produced a long list of downstream interventions; a company betting on the prescription itself as the point of use is making a more specific wager, and one worth tracking.
Pulse Raman covers biotech, digital health, and clinical AI for Startuply. The patient outcome is the lede.